Loading
Lung Cancer Treatments and Mutations / Lung Cancer Diagnosis and Treatment · Journal article
JAMA · August 10, 2026
Well-designed and adequately powered for the question it asks.
This phase 3 trial demonstrates that first-line osimertinib plus chemotherapy significantly prolongs progression-free survival compared to osimertinib monotherapy in patients with EGFR-mutated advanced NSCLC harbouring concurrent TP53 mutations, with a median PFS difference of 18.4 months. Overall survival data remain immature (30.6% maturity) and show only a trend toward benefit. The combination approach carries a higher burden of grade 3+ adverse events but introduces no new safety signals.
Multicenter, randomized, open-label, phase 3 trial. Treatment-naive adults with stage IV or recurrent nonsquamous NSCLC harbouring concurrent TP53 and EGFR-sensitizing mutations; 294 enrolled (median age 57 years, 54.1% female).. Intervention: Osimertinib plus chemotherapy: pemetrexed and carboplatin every 3 weeks for 4 cycles, followed by maintenance osimertinib plus pemetrexed. Compared with: Osimertinib monotherapy. n = 294. 17 sites in China.
Median PFS: 34.0 months (osimertinib + chemotherapy) vs 15.6 months (osimertinib monotherapy); difference 18.4 months (95% CI 9.9–22.3) Hazard ratio for PFS: 0.44 (95% CI 0.32–0.60; p <.001) Benefit consistent across prespecified subgroups including brain metastases and L858R mutations
Specific incidence rates and grades of individual adverse events not detailed in this abstract Grade 3 or higher treatment-related adverse events higher in combination group; no new safety signal identified
This trial provides evidence to support first-line osimertinib plus chemotherapy in patients with EGFR-mutated advanced NSCLC and concurrent TP53 mutations, a population previously identified as potentially benefiting from combination strategies. Clinicians should weigh the 18.4-month PFS improvement against higher toxicity burden and the lack of mature OS data (currently 30.6% maturity), and consider this approach in the context of individual patient factors and tolerance for adverse events.
Phase 3 RCT with adequately powered, pre-specified primary endpoint showing clinically significant and statistically robust PFS benefit (HR 0.44, p<.001) in a well-defined population, though OS remains immature and generalizability is limited to China.
As stated by the source record.
Quoted from the source exactly as published.
This trial provides evidence to support first-line osimertinib plus chemotherapy in patients with EGFR-mutated advanced NSCLC and concurrent TP53 mutations, a population previously identified as potentially benefiting from combination strategies. Clinicians should weigh the 18.4-month PFS improvement against higher toxicity burden and the lack of mature OS data (currently 30.6% maturity), and consider this approach in the context of individual patient factors and tolerance for adverse events.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Importance: Combination therapy has emerged as a promising therapeutic approach for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, its clinical benefit-risk profile remains a focus of ongoing debate. Identifying patients most likely to derive benefit from such regimens remains an unmet clinical need. Objective: To prospectively compare the efficacy and safety of first-line osimertinib plus chemotherapy with osimertinib monotherapy for patients with EGFR-mutated advanced NSCLC harboring concurrent TP53 mutations. Design, Setting, and Participants: A multicenter, randomized, open-label, phase 3 study conducted at 17 sites in China. Between March 25, 2021, and July 11, 2024, a total of 294 eligible patients with treatment-naive, stage IV or recurrent nonsquamous NSCLC harboring concurrent TP53 and EGFR-sensitizing mutations were enrolled. Interventions: Patients were randomized (1:1) to receive osimertinib plus chemotherapy (pemetrexed and carboplatin every 3 weeks for 4 cycles, followed by maintenance therapy of osimertinib plus pemetrexed; n = 146) or osimertinib monotherapy (n = 148). Main Outcomes and Measures: The primary end point was investigator-assessed progression-free survival. Secondary end points included overall survival, response, safety, and quality of life. Results: Among 294 enrolled patients, the median age was 57 years (range, 26-79 years), and 159 (54.1%) were female. The data cutoff date was November 11, 2025. At a median follow-up of 25.1 months for the osimertinib-chemotherapy group and 26.1 months for the osimertinib monotherapy group, median progression-free survival was significantly longer with osimertinib plus chemotherapy than with osimertinib monotherapy (34.0 vs 15.6 months; difference, 18.4 months [95% CI, 9.9-22.3]; hazard ratio, 0.44 [95% CI, 0.32-0.60]; P <.001). This benefit was consistent across prespecified subgroups, including those with brain metastases and L858R mutations. The overall survival data remained immature (30.6% maturity); however, a trend toward overall survival benefit with combination therapy was observed. The incidence of grade 3 or higher treatment-related adverse events was higher in the combination group, with no new safety signal identified. Conclusions and Relevance: In this randomized clinical trial, osimertinib plus chemotherapy significantly increased progression-free survival among patients with EGFR-mutated advanced NSCLC harboring concurrent TP53 mutations. These findings provided a clinical rationale for individualized combination strategies in the management of patients with EGFR-mutated NSCLC. Trial Registration: ClinicalTrials.gov Identifier: NCT04695925.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.